Latest News
Notice of General Meeting
21 April 2020
Clinical pipeline update, resolutions seeking shareholder authority to issue new ordinary shares for cash and approval of proposed option grant
London, New York 21 April 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), the...
Update Re: Block Listing Application
15 April 2020
London / New York 15 April 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), the U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human...
Issue of Equity and Resulting Total Voting Rights
15 April 2020
Issue of Equity and Resulting Total Voting Rights
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
London / New York 15 April 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company"...
Block Listing Application and "At The Market" Sales Agreement
15 April 2020
Block Listing Application and "At The Market" Sales Agreement
London / New York 15 April 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), the U.S. and U.K. biotechnology company that focuses on the discovery...
Tiziana Life Sciences Develops Novel Investigational Treatment For Patients Infected with COVID-19 Utilizing Direct Delivery of Anti-Interlukin-6-Receptor Monoclonal Antibodies
09 April 2020
Company Has Filed Patent Application in Support of Treatment of COVID-19 Utilizing Anti-IL6R Via Inhaled Delivery
New York/London -- April 9, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative...
Tiziana Announces Closing of Offering and Resulting Total Voting Rights
16 March 2020
London, New York 16 March 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human...